Autologous Dendritic Cell/Myeloma Fusion Vaccine

**Semantic type:** Cell|Immunologic Factor|Pharmacologic Substance

**Definition:** A therapeutic cancer vaccine consisting of autologous dendritic cells (DCs) fused with patient-derived plasma cell (multiple) myeloma cells with potential immunostimulatory and antineoplastic activities. Upon administration, autologous DC/multiple myeloma fusions stimulate both helper and cytotoxic T-lymphocyte (CTL) responses through the presentation of internalized and newly synthesized tumor associated antigens (TAAs). This may promote cellular and humoral antitumor immune responses in patients with plasma cell myeloma.

**Synonyms:** - Autologous DC/Multiple Myeloma Fusions - DC/MM Fusion Vaccine - DC/MM Fusions - DC/Multiple Myeloma Fusions - DC/Plasma Cell Myeloma Fusion